Cost minimization analysis of Herceptin subcutaneous versus Herceptin intravenous treatment for patients with HER2+ Breast cancer in Greece
Sign Up to like & getrecommendations! Published in 2017 at "Journal of cancer policy"
DOI: 10.1016/j.jcpo.2017.05.001
Abstract: Abstract Aim To conduct an economic evaluation comparing Herceptin subcutaneous formulation (Herceptin-SC) with Herceptin intravenous formulation (Herceptin-IV), in the treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early and metastatic breast cancer… read more here.
Keywords: herceptin subcutaneous; herceptin; herceptin herceptin; treatment ... See more keywords